Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5731002 – Disitamab Vedotin Alone or with Pembrolizumab in HER2-Expressing Urothelial Carcinoma
2022-500030-28-01Phase 2Authorised
- Sponsor
- Seagen Inc.
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label trial of disitamab vedotin in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Confirmed Objective Response Rate (cORR) by BICR – Cohort-specific and Confirmed Objective Response Rate (cORR) by BICR – Overall. Planned start Jun 2024; status: authorised.
02
Drugs
disitamab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-500030-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500030-28-01.